{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:21:22Z","timestamp":1787934082026,"version":"build-2784847793"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI137472"],"award-info":[{"award-number":["R01AI137472"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI139092"],"award-info":[{"award-number":["R01AI139092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.trsl.2021.11.007","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T09:37:45Z","timestamp":1637314665000},"page":"20-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Advances in mRNA and other vaccines against MERS-CoV"],"prefix":"10.1016","volume":"242","author":[{"given":"Wanbo","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2021.11.007_bib0001","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","article-title":"Subunit vaccines against emerging pathogenic human coronaviruses","volume":"11","author":"Wang","year":"2020","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.trsl.2021.11.007_bib0002","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/14760584.2020.1813574","article-title":"An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies","volume":"19","author":"Zhang","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.trsl.2021.11.007_bib0003","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14728222.2020.1820482","article-title":"Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2","volume":"25","author":"Jiang","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"10.1016\/j.trsl.2021.11.007_bib0004","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14760584.2014.912134","article-title":"Current advancements and potential strategies in the development of MERS-CoV vaccines","volume":"13","author":"Zhang","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.trsl.2021.11.007_bib0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0006","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.007_bib0007","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","article-title":"Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003","volume":"362","author":"Zhong","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2021.11.007_bib0008","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.007_bib0009","unstructured":"World Health Organization. Middle East respiratory syndromes (MERS) situation update. October 2021. Available at: http:\/\/www.emro.who.int\/health-topics\/mers-cov\/mers-outbreaks.html."},{"key":"10.1016\/j.trsl.2021.11.007_bib0010","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/v11070663","article-title":"MERS coronavirus: an emerging zoonotic virus","volume":"11","author":"Li","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.trsl.2021.11.007_bib0011","doi-asserted-by":"crossref","first-page":"12516","DOI":"10.1073\/pnas.1405889111","article-title":"Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus","volume":"111","author":"Yang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2021.11.007_bib0012","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.chom.2014.08.009","article-title":"Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26","volume":"16","author":"Wang","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.trsl.2021.11.007_bib0013","doi-asserted-by":"crossref","first-page":"21878","DOI":"10.1038\/srep21878","article-title":"Replication and shedding of MERS-CoV in Jamaican fruit bats (Artibeus jamaicensis)","volume":"6","author":"Munster","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0014","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1473-3099(13)70690-X","article-title":"Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation","volume":"14","author":"Haagmans","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.007_bib0015","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(20)30607-3","article-title":"First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA","volume":"395","author":"Ghinai","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2021.11.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.35057","article-title":"SARS-CoV-2 transmission from people without COVID-19 symptoms","volume":"4","author":"Johansson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.trsl.2021.11.007_bib0017","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJMoa1405858","article-title":"Transmission of MERS-coronavirus in household contacts","volume":"371","author":"Drosten","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.007_bib0018","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41598-019-57216-x","article-title":"Infection prevention measures for surgical procedures during a Middle East respiratory syndrome outbreak in a tertiary care hospital in South Korea","volume":"10","author":"Park","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0019","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4266\/acc.2021.00388","article-title":"Comparison of characteristics and ventilatory course between coronavirus disease 2019 and Middle East respiratory syndrome patients with acute respiratory distress syndrome","volume":"36","author":"Khalid","year":"2021","journal-title":"Acute Crit Care"},{"key":"10.1016\/j.trsl.2021.11.007_bib0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/v11010060","article-title":"Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain","volume":"11","author":"Zhou","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.trsl.2021.11.007_bib0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14728222.2017.1271415","article-title":"MERS-CoV spike protein: a key target for antivirals","volume":"21","author":"Du","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.trsl.2021.11.007_bib0022","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102983118","article-title":"Middle East respiratory syndrome coronavirus spike protein variants exhibit geographic differences in virulence","volume":"118","author":"Wong","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2021.11.007_bib0023","doi-asserted-by":"crossref","first-page":"e01651","DOI":"10.1128\/JVI.01651-16","article-title":"Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants","volume":"91","author":"Tai","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0024","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12985-021-01563-7","article-title":"Sequence and phylogentic analysis of MERS-CoV in Saudi Arabia, 2012-2019","volume":"18","author":"Farrag","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.trsl.2021.11.007_bib0025","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.1128\/JVI.01756-13","article-title":"Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus","volume":"87","author":"Chen","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0026","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.11.007_bib0027","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","article-title":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4","volume":"23","author":"Wang","year":"2013","journal-title":"Cell Res"},{"key":"10.1016\/j.trsl.2021.11.007_bib0028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.007_bib0029","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.trsl.2021.11.007_bib0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.007_bib0031","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.007_bib0032","doi-asserted-by":"crossref","first-page":"E8508","DOI":"10.1073\/pnas.1712592114","article-title":"Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2021.11.007_bib0033","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.03","article-title":"Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus","volume":"13","author":"Zhang","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0034","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1016\/j.vaccine.2014.08.086","article-title":"Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments\u2013the importance of immunofocusing in subunit vaccine design","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2021.11.007_bib0035","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.trsl.2021.11.007_bib0036","doi-asserted-by":"crossref","first-page":"13473","DOI":"10.1038\/ncomms13473","article-title":"Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines","volume":"7","author":"Du","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.11.007_bib0037","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","article-title":"A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection","volume":"499","author":"Tai","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.trsl.2021.11.007_bib0038","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1038\/ncomms8712","article-title":"Evaluation of candidate vaccine approaches for MERS-CoV","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.11.007_bib0039","doi-asserted-by":"crossref","first-page":"8223","DOI":"10.1038\/ncomms9223","article-title":"Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody","volume":"6","author":"Ying","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.11.007_bib0040","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.celrep.2019.08.052","article-title":"Structural definition of a neutralization-sensitive epitope on the MERS-CoV S1-NTD","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0041","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1128\/JVI.00433-14","article-title":"A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein","volume":"88","author":"Du","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0042","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.00912-14","article-title":"Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies","volume":"88","author":"Ying","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0043","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41467-019-10897-4","article-title":"Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.11.007_bib0044","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.celrep.2018.06.041","article-title":"Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein","volume":"24","author":"Zhang","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0045","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3201\/eid2705.204056","article-title":"Longevity of Middle East respiratory syndrome coronavirus antibody responses in humans, Saudi Arabia","volume":"27","author":"Alshukairi","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.007_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104820","article-title":"Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2","volume":"179","author":"Tai","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trsl.2021.11.007_bib0047","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0048","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41422-020-0387-5","article-title":"A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2","volume":"30","author":"Tai","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.trsl.2021.11.007_bib0049","doi-asserted-by":"crossref","first-page":"eabf1591","DOI":"10.1126\/sciadv.abf1591","article-title":"Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates","volume":"7","author":"He","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.trsl.2021.11.007_bib0050","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.007_bib0051","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.007_bib0052","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","volume":"20","author":"Koch","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.007_bib0053","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2021.11.007_bib0054","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1128\/JVI.01815-15","article-title":"A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant Measles virus vaccine platform","volume":"89","author":"Malczyk","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0055","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1016\/j.vaccine.2020.07.003","article-title":"Vaccines based on virus-like nano-particles for use against Middle East respiratory syndrome (MERS) coronavirus","volume":"38","author":"Hashemzadeh","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2021.11.007_bib0056","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00103-21","article-title":"Genetically engineered live-attenuated Middle East respiratory syndrome coronavirus viruses confer full protection against lethal infection","volume":"12","author":"Guti\u00e9rrez-\u00c1lvarez","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.trsl.2021.11.007_bib0057","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146082","article-title":"Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus","volume":"6","author":"Patel","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.trsl.2021.11.007_bib0058","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00554-20","article-title":"Single-dose, intranasal immunization with fecombinant parainfluenza virus 5 expressing Middle East respiratory syndrome coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV infection","volume":"11","author":"Li","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.trsl.2021.11.007_bib0059","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/vaccines8040635","article-title":"Conjugation of human \u03b2-Defensin 2 to spike protein receptor-binding domain induces antigen-specific protective immunity against Middle East respiratory syndrome coronavirus infection in human dipeptidyl peptidase 4 transgenic mice","volume":"8","author":"Kim","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2021.11.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201807616","article-title":"Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East respiratory syndrome coronavirus","volume":"29","author":"Lin","year":"2019","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.trsl.2021.11.007_bib0061","doi-asserted-by":"crossref","first-page":"44875","DOI":"10.1038\/srep44875","article-title":"Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike","volume":"7","author":"Al-Amri","year":"2017","journal-title":"Protein Sci Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0062","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1517\/14712598.2015.1092518","article-title":"Middle East respiratory syndrome: current status and future prospects for vaccine development","volume":"15","author":"Du","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.trsl.2021.11.007_bib0063","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14760584.2018.1506702","article-title":"Prospects for a MERS-CoV spike vaccine","volume":"17","author":"Zhou","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.trsl.2021.11.007_bib0064","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1586\/14760584.2016.1167603","article-title":"Vaccines for the prevention against the threat of MERS-CoV","volume":"15","author":"Du","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.trsl.2021.11.007_bib0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41541-021-00303-w","article-title":"Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2","volume":"6","author":"Cho","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.trsl.2021.11.007_bib0066","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.vaccine.2017.02.063","article-title":"DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice","volume":"35","author":"Chi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2021.11.007_bib0067","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/21645515.2017.1296994","article-title":"Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection","volume":"13","author":"Wang","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.trsl.2021.11.007_bib0068","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.1128\/JVI.01048-13","article-title":"Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development","volume":"87","author":"Du","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0069","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.vaccine.2018.02.065","article-title":"Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen","volume":"36","author":"Nyon","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2021.11.007_bib0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/vaccines8020251","article-title":"The potency of an anti-MERS coronavirus subunit vaccine depends on a unique combinatorial adjuvant formulation","volume":"8","author":"George","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2021.11.007_bib0071","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01176-20","article-title":"Cross-protection against MERS-CoV by prime-boost vaccination using viral spike DNA and protein","volume":"94","author":"Choi","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0072","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1080\/22221751.2020.1760735","article-title":"Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV","volume":"9","author":"Okba","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.trsl.2021.11.007_bib0073","doi-asserted-by":"crossref","first-page":"114","DOI":"10.32607\/actanaturae.11042","article-title":"Preclinical studies of immunogenity, potectivity, and safety of the combined vector vaccine for prevention of the Middle East respiratory syndrome","volume":"12","author":"Dolzhikova","year":"2020","journal-title":"Acta Naturae"},{"key":"10.1016\/j.trsl.2021.11.007_bib0074","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/v12010125","article-title":"Characterization of the immune response of MERS-CoV vaccine candidates derived from two different vectors in mice","volume":"12","author":"Li","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.trsl.2021.11.007_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223684","article-title":"Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.11.007_bib0076","doi-asserted-by":"crossref","first-page":"16292","DOI":"10.1038\/s41598-019-52730-4","article-title":"Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels","volume":"9","author":"Alharbi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0077","article-title":"Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length spike protein of Middle East respiratory syndrome coronavirus","volume":"14","author":"Kim","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.11.007_bib0078","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.aad1283","article-title":"An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels","volume":"351","author":"Haagmans","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.trsl.2021.11.007_bib0079","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245072","article-title":"Rational design of multi epitope-based subunit vaccine by exploring MERS-CoV proteome: reverse vaccinology and molecular docking approach","volume":"16","author":"Ashfaq","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.11.007_bib0080","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.trsl.2021.11.007_bib0081","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0082","doi-asserted-by":"crossref","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.11.007_bib0083","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/vaccines7030096","article-title":"Immunogenicity and protection efficacy of a naked self-replicating mRNA-based Zika virus vaccine","volume":"7","author":"Zhong","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2021.11.007_bib0084","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.11.007_bib0085","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2021.11.007_bib0086","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/vaccines8010123","article-title":"mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice","volume":"8","author":"Zhuang","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2021.11.007_bib0087","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","article-title":"Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques","volume":"15","author":"Pardi","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.trsl.2021.11.007_bib0088","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2018.10.010","article-title":"Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA","volume":"12","author":"Moyo","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.trsl.2021.11.007_bib0089","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.007_bib0090","article-title":"mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants","volume":"2021","author":"Wu","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.trsl.2021.11.007_bib0091","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1021\/acs.nanolett.1c01284","article-title":"Lipid nanoparticle RBD-hFc mRNA vaccine protects hACE2 transgenic mice against a lethal SARS-CoV-2 infection","volume":"21","author":"Elia","year":"2021","journal-title":"Nano Lett"},{"key":"10.1016\/j.trsl.2021.11.007_bib0092","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0093","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001812","article-title":"Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery","volume":"10","author":"Ho","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.trsl.2021.11.007_bib0094","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/vaccines2040735","article-title":"Self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles","volume":"2","author":"McCullough","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2021.11.007_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.608460","article-title":"RNA vaccines: A suitable platform for tackling emerging pandemics?","volume":"11","author":"Sandbrink","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0096","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.trsl.2021.11.007_bib0097","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/vaccines9040390","article-title":"mRNA-based vaccines","volume":"9","author":"Kowalzik","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2021.11.007_bib0098","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/vaccines9020148","article-title":"mRNA vaccines against flaviviruses","volume":"9","author":"Wollner","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2021.11.007_bib0099","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/17460441.2021.1935859","article-title":"An overview of rational design of mRNA-based therapeutics and vaccines","author":"To","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.trsl.2021.11.007_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","article-title":"mRNA vaccine: a potential therapeutic strategy","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2021.11.007_bib0101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2021.11.007_bib0102","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1367","article-title":"Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease","volume":"9","author":"Hadas","year":"2017","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"10.1016\/j.trsl.2021.11.007_bib0103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.trsl.2021.11.007_bib0104","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/vaccines9050452","article-title":"Construction and immunogenicity of modified mRNA-vaccine variants encoding influenza virus antigens","volume":"9","author":"Starostina","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2021.11.007_bib0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coviro.2021.03.008","article-title":"Future considerations for the mRNA-lipid nanoparticle vaccine platform","volume":"48","author":"Igy\u00e1rt\u00f3","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0106","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"2021","author":"Ndeupen","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.trsl.2021.11.007_bib0107","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The Advisory Committee on immunization practices' interim recommendation for use of Moderna COVID-19 vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0108","doi-asserted-by":"crossref","first-page":"749","DOI":"10.15585\/mmwr.mm7020e1","article-title":"The Advisory Committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years - United States, May 2021","volume":"70","author":"Wallace","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0109","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0110","doi-asserted-by":"crossref","first-page":"674","DOI":"10.15585\/mmwr.mm7018e1","article-title":"Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged \u226565 Years - United States, January-March 2021","volume":"70","author":"Tenforde","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0111","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.934625","article-title":"Editorial: first full regulatory approval of a COVID-19 vaccine, the BNT162b2 Pfizer-BioNTech vaccine, and the real-world implications for public health policy","volume":"27","author":"Parums","year":"2021","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.trsl.2021.11.007_bib0112","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.15585\/mmwr.mm7038e2","article-title":"Use of Pfizer-BioNTech COVID-19 vaccine in persons aged \u226516 years: recommendations of the Advisory Committee on immunization practices - United States, September 2021","volume":"70","author":"Dooling","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0113","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.trsl.2021.11.007_bib0114","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.15585\/mmwr.mm7031e1","article-title":"COVID-19 vaccine safety in adolescents aged 12-17 years - United States, December 14, 2020-July 16, 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0115","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15585\/mmwr.mm7044e2","article-title":"The Advisory Committee on Immunization Practices' Interim Recommendations for additional primary and booster doses of COVID-19 vaccines - United States, 2021","volume":"70","author":"Mbaeyi","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0116","doi-asserted-by":"crossref","first-page":"651","DOI":"10.15585\/mmwr.mm7017e4","article-title":"Updated recommendations from the Advisory Committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with Thrombocytopenia syndrome among vaccine recipients - United States, April 2021","volume":"70","author":"MacNeil","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0117","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.007_bib0118","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice","volume":"53","author":"Laczk\u00f3","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2021.11.007_bib0119","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.007_bib0120","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01381-18","article-title":"Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization","volume":"93","author":"Kleine-Weber","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0121","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.11.007_bib0122","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.007_bib0123","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1126\/science.abi7994","article-title":"SARS-CoV-2 immune evasion by the B.1.427\/B.1.429 variant of concern","volume":"373","author":"McCallum","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.trsl.2021.11.007_bib0124","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.11.007_bib0125","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.cell.2021.02.042","article-title":"SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.11.007_bib0126","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.trsl.2021.11.007_bib0127","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00116-18","article-title":"Discovery of novel bat coronaviruses in South China that use the same receptor as Middle East Respiratory syndrome coronavirus","volume":"92","author":"Luo","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0128","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4049\/jimmunol.2100421","article-title":"Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity","volume":"207","author":"Matchett","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2021.11.007_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109107","article-title":"A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage","volume":"35","author":"Gambino","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.trsl.2021.11.007_bib0130","doi-asserted-by":"crossref","first-page":"eabb2154","DOI":"10.1126\/sciadv.abb2154","article-title":"CD8+ T cells mediate protection against Zika virus induced by an NS3-based vaccine","volume":"6","author":"Elong Ngono","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.trsl.2021.11.007_bib0131","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421002802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421002802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:45:41Z","timestamp":1761828341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524421002802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":131,"alternative-id":["S1931524421002802"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2021.11.007","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in mRNA and other vaccines against MERS-CoV","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2021.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}